Skip to main content
  • DE
  • EN
  • FR
Paul Scherrer Institut (PSI) Paul Scherrer Institut (PSI)
Suche
Paul Scherrer Institut (PSI) Paul Scherrer Institut (PSI)

Hauptnavigation

  • Labs & User ServicesOpen mainmenu item
    • Overview
    • Research at PSI
    • Research Divisions and Labs
    • Facilities and Instruments
    • Research Initiatives
    • PSI User Labs
    • Scientific Highlights
    • Scientific Events
    • Scientific Career
    • Useroffice
  • VisitorsOpen mainmenu item
    • Overview
    • Contact
    • How to find us
    • Public Events
    • Visitor Centre psi forum
    • Schülerlabor iLab
    • Center for Proton Therapy
  • IndustryOpen mainmenu item
    • Overview
    • Technology Transfer
    • Spin-off Companies
    • PARK innovAARE
  • Our ResearchOpen mainmenu item
    • Current topics from our research
    • Matter and Material
    • Human Health
    • Energy and Environment
    • Large Research Facilities
    • Brochures
    • Films
    • Media Corner
  • Career & Further EducationOpen mainmenu item
    • Job Opportunities
    • Personnel Policy
    • Working at PSI
    • Equal Opportunities, Diversity & Inclusion
    • Training and Further Education
    • Vocational Training
    • PSI Education Centre
    • Support Program "PSI Career Return Program"
    • PSI-FELLOW/COFUND
  • About PSIOpen mainmenu item
    • PSI in brief
    • Strategy
    • Guiding principles
    • Facts and figures
    • Organisational structure
    • Suppliers and customers
    • Customers E-Billing
    • IT and Computing
    • Safety at PSI (in German)

You are here:

  1. PSI Home
  2. Our Research
  3. Current topics from our research
  4. Radiopharmacy

Secondary navigation

Our Research

  • Current topics from our research Expanded submenu item
    • Matter and Material
    • Human Health
    • Energy and Environment
    • ESI Platform
    • Large research facilities
    • Project SLS 2.0
    • Topic Overview
    • Chronological Overview
      • Archiv
  • 5232 – The magazine of the Paul Scherrer Institute
    • Contact
  • Brochures
  • Films
    • Virtual Tour
  • Media corner
    • Media Releases
    • Social Media Newsroom

Radiopharmacy

14 October 2020
Doming

A protein's unexpected "doming"

Human Health Medical Science Radiopharmacy

Researchers have coaxed a secret out of the vital protein cytochrome c that it kept well-hidden up to now. Measurements at the X-ray free-electron laser SwissFEL reveal structural changes that science had previously ruled out for this kind of biomolecule.

Read more
5 October 2020
teaser

More effective treatment of thyroid cancer

Human Health Medical Science Radiopharmacy

PSI researchers have found a more effective treatment for a form of thyroid cancer – and with fewer side effects – by increasing the uptake of the cancer drug in tumour cells. The results have been published in the medical journal Theranostics.

Read more
26 November 2019
Teaser Medikamente mit Strahlkraft

Brilliant medicines

Biology Human Health Radiopharmacy Medical Science

In the service of health, scientists at the Paul Scherrer Institute PSI work with radionuclides and develop agents to treat cancer and to detect tumours. Their research provides support to hospitals and is of great interest to Swiss industry.

Read more
11 October 2018

Licence agreement with Swiss pharma firm for development of a cancer drug

Medical Science Human Health Radiopharmacy Industrial co-operation

A radioactive agent, developed at the Paul Scherrer Institute PSI to fight an especially malignant form of thyroid cancer, has the potential to become a blockbuster drug. Due to its structure, it might also be able to dock onto cells of other tumours and destroy them with its radiation. The Lausanne-based biopharmaceutical company Debiopharm wants to further develop the PSI agent to the point where it is approved as a drug. Debiopharm and PSI have now created the contractual basis for this.

Read more
22 August 2018

A biotechnological revolution

Biology Medical Science Human Health Radiopharmacy

Gebhard Schertler is head of the research division Biology and Chemistry at the Paul Scherrer Institute PSI and professor for Structural Biology at ETH Zurich. In this interview he talks about biological research at PSI and the future of drug development.

Read more
8 November 2017

A new bio-robot

Media Releases Biology Human Health Industrial co-operation Radiopharmacy

With a new method for modifying antibodies, Philipp Spycher, winner of a Founder Fellowship at the Paul Scherrer Institute PSI, wants to develop drugs that are more stable and, thus, have fewer side-effects.

Read more
12 December 2016

In the focus of the protons

Medical Science Human Health Radiopharmacy

At the PSI, researchers work with radioactivity every day in order to develop advanced treatment methods for patients. Naturally, they take special safety precautions working with a material that decays. It's a race against time. To make sure everything functions smoothly, a dedicated work group takes care of the infrastructure.

Read more
26 July 2016

Designer nuclide for medical applications

Medical Science Human Health Radiopharmacy

Researchers at the PSI have for the first time used a cyclotron to produce the radionuclide scandium-44 in a quantity and concentration as needed for medical treatment. With that, they have achieved the first precondition for scandium-44 to be used one day for medical tests in hospitals.

Read more
21 April 2016

Hitting cancer from the inside

Medical Science Human Health Radiopharmacy

Researchers at the Paul Scherrer Institute PSI are now investigating a new method to channel radioactive substances directly into the nucleus of a cancer cell. Through this approach, the radiation source remains inside the cell and works in a more targeted way, because it gets closer to the cell's genetic information.

Read more
3 March 2016

Medicines made to order with pinpoint precision

Medical Science Human Health Radiopharmacy

At PSI, scientists are developing new medicines against cancer. These contain radioactive substances that can be injected into the patients and thus make their way to the tumour. There, in direct contact, their radiation should destroy the cancer cells. Before such a radioactive medicine can be tested on patients in the first clinical trials, however, its safety must be guaranteed to ensure that the patient will not be harmed. Therefore every agent is produced at the PSI under sterile conditions and tested – separately for each patient, and only on the doctor's order.

Read more
17 February 2016

Developing a new drug against thyroid cancer

Medical Science Human Health Radiopharmacy

Researchers at the Paul Scherrer Institute PSI have developed a drug to trace and treat a particularly malignant strain of thyroid cancer more effectively. One advantage of the new drug is that it can be used to treat a strain of thyroid cancer where the established treatment is ineffective. The researchers at PSI have developed the new drug to such an extent that an initial study conducted on cancer patients at the University Hospital Basel can now get underway.

Read more
14 January 2016

Targeting cancer

Medical Science Human Health Radiopharmacy

There are tumours where nothing seems to help: not chemotherapy, not external radiation therapy, not an operation. Often, they have already metastasised and can no longer be destroyed using conventional methods. The only option left here is internal radiotherapy with targeted radioactive drugs that strike directly at the heart of the disease. In order to make this possible, twenty specialists have been conducting research at the Centre for Radiopharmaceutical Sciences at the Paul Scherrer Institute PSI, a joint facility of PSI, ETH Zurich and the University Hospital Zurich.

Read more
This is a text from the PSI media archive. The contents may be out-of-date.
Topic Overview

Sidebar

5232 Ausgabe 3 2020

5232 — Das Magazin des Paul Scherrer Instituts

03/2020
in German
View in issuu.com
Download

Visitor Centre psi forum

Experience research live


The iLab School Laboratory

Experience Science - Explore Research

top

Footer

Paul Scherrer Institut

Forschungsstrasse 111
5232 Villigen PSI
Switzerland
How to find us

Imprint
Terms and Conditions

Login

Telephone: +41 56 310 21 11
Telefax: +41 56 310 21 99
Contact form

Visitor Centre psi forum
School Lab iLab (in German)
Center for Proton Therapy

Follow us: Twitter (in English) LinkedIn Youtube Issuu RSS

Quicklinks

  • Phone Book/People Search
  • Digital User Office
  • Technology transfer
  • PSI Publications
  • Computing
  • Safety (in German)
  • Job Opportunities
  • Vocational Training (in German)
  • Suppliers
  • Customers E-Billing
  • PSI Guest House
  • PSI Gastronomie (in German)

For the media

  • Media Contact
  • Media Releases
  • Social Media Newsroom
  • Facts and Figures
  • PSI in brief
  • Films
  • DE
  • EN
  • FR